Market Tracker

12/05 7:20am ET

Athersys Inc (NASDAQ:ATHX)

1.56
Delayed Data
As of Dec 02
 0.00 / 0.00%
Today’s Change
0.97
Today|||52-Week Range
2.90
+51.46%
Year-to-Date
Foamix Completes Enrolment in Phase III Acne Drug Studies
Nov 30 / Zacks.com - Paid Partner Content
Epizyme Tazemetostat Gets Fast Track Designation in U.S.
Nov 29 / Zacks.com - Paid Partner Content
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
Nov 30 / Zacks.com - Paid Partner Content
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health
Nov 25 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close1.56
Today’s open1.56
Day’s range1.54 - 1.60
Volume213,286
Average volume (3 months)358,396
Market cap$133.4M
Dividend yield--
Data as of 12/02/2016

Growth & Valuation

Earnings growth (last year)+35.48%
Earnings growth (this year)+5.00%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+636.17%
P/E ratioNM
Price/Sales7.14
Price/Book6.62

Competitors

 Today’s
change
Today’s
% change
RGLSRegulus Therapeutics...+0.10+4.17%
CXRXConcordia Internatio...+0.10+4.02%
ZYNEZynerba Pharmaceutic...+0.83+6.48%
CTICCTi Biopharma Corp+0.04+9.60%
Data as of 12/02/2016

Financials

Next reporting dateMarch 16, 2017
EPS forecast (this quarter)-$0.08
Annual revenue (last year)$11.9M
Annual profit (last year)-$16.4M
Net profit margin-137.45%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Gil van Bokkelen
President, Chief Operating Officer &
Secretary
William B. J. Lehmann
Corporate headquarters
Cleveland, Ohio

Forecasts